ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular

A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter Study of ZG005 in Combination With Bevacizumab Versus Sintilimab in Combination With Bevacizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma

The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC

Inclusion Criteria:

• Participants with histologically/cytologically confirmed unresectable or metastatic advanced HCC;
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Barcelona Clinic Liver Cancer stage B, not suitable for local treatment and BCLC C.
• At least one measurable lesion based on Recist1.1.
• No prior systemic therapy for HCC.
• Child-Pugh ≤6 , no history of hepatic encephalopathy.

Exclusion Criteria:

• Active Central nervous system (CNS) metastasis or leptomeningeal metastases.
• Any condition that is not suitable for participate in this study as determined by investigator.